Gene editing

"In 2023, therapeutic gene editing moved from promise to reality with the first approved CRISPR-based therapy, CASGEVY, which has since received regulatory clearance in multiple regions for the treatment of sickle cell disease and beta thalassemia."https://crisprmedicinenews.com/clinical-trials/?utm_source=join1440&utm_medium=email&utm_placement=newsletter&user_id=66c4c92f5d78644b3ac5d5b4